<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393754</url>
  </required_header>
  <id_info>
    <org_study_id>Sci-B-Vac-001</org_study_id>
    <secondary_id>2017-001819-36</secondary_id>
    <nct_id>NCT03393754</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.</brief_title>
  <official_title>A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VBI Vaccines Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VBI Vaccines Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a double-blind randomized controlled trial designed to establish the
      non-inferiority of Sci-B-Vac™ compared to Engerix-B® in adults ≥ 18 years old and the
      superiority of Sci-B-Vac™ compared to Engerix-B® in ≥ 45 years old.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-blind randomized controlled trial designed to establish the
      non-inferiority of Sci-B-Vac compared to Engerix-B® in adults ≥ 18 years old and the
      superiority of Sci-B-Vac™ compared to Engerix-B® in adults ≥ 45 years old. Study subjects
      will be randomized 1:1 to receive either a total of 3 injections of Sci-B-Vac™ or 3
      injections of Engerix-B® intra-muscularly (IM) on Days 0, 28, and 168.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprotection rate at Day 196 in adults ≥ 18 years old</measure>
    <time_frame>Day 196</time_frame>
    <description>Seroprotection rate (SPR) achieved on Study Day 196, 4 weeks post-third vaccination with either Sci-B-Vac™ or Engerix-B® in adults ≥18 years old.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection rate at Day 196 in adults ≥ 45 years old</measure>
    <time_frame>Day 196</time_frame>
    <description>Seroprotection rate (SPR) achieved on Study Day 196, 4 weeks post-third vaccination with either Sci-B-Vac™ or Engerix-B® in adults ≥45 years old.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rate after Dose 2</measure>
    <time_frame>4 weeks and 20 weeks, post-second injection</time_frame>
    <description>The SPR after 2 doses of Sci-B-Vac (at either 4 or 20 weeks after vaccination) is being compared to the SPR achieved after the 3rd vaccination of Engerix-B (4 weeks after 3rd vaccination).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subject-reported, solicited, and unsolicited adverse events</measure>
    <time_frame>Up to Study Day 336</time_frame>
    <description>Number (%) of subject-reported, solicited (on the day of vaccination and during the next 6 days), unsolicited adverse events (AE) (on the day of vaccination and during the next 27 days), and number (%) of Serious Adverse Events (SAEs), medically significant events or new onset of chronic illness through Study Day 336.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal vital signs</measure>
    <time_frame>Up to Study Day 336</time_frame>
    <description>Number (%) of subjects with abnormal vital signs (including oral temperature, blood pressure (systolic/diastolic), heart rate, and respiratory rate will be assessed at baseline and at each vaccination visit) and/or full physical examination findings, compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1564</enrollment>
  <condition>Hepatitis B Vaccines</condition>
  <arm_group>
    <arm_group_label>Sci-B-Vac Hepatitis B Vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sci-B-Vac (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 10ug, IM injection at Days 0, 28, and 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Engerix-B Hepatitis B Vaccination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Engerix-B® (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 20ug, IM injection at Days 0, 28, and 168.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B Vaccination</intervention_name>
    <description>Prophylactic Hepatitis B Vaccination</description>
    <arm_group_label>Sci-B-Vac Hepatitis B Vaccination</arm_group_label>
    <arm_group_label>Engerix-B Hepatitis B Vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any gender.

          -  Age ≥ 18 years

          -  In stable health as determined by a physical examination and laboratory tests values.
             Common chronic conditions such as, but not limited to, type 2 diabetes, high blood
             pressure, Chronic Obstructive Pulmonary Disease (COPD) and asthma will be accepted if
             the condition is well controlled, as determined by the investigator, and not meeting
             the exclusion criteria. For subjects &gt; 65 years old, Frailty Index ≤3

          -  If female, either is not of childbearing potential or is of childbearing potential and
             must agree to use an adequate birth control method during the screening period and
             until the end of her participation in the study

          -  Able and willing to give consent.

        Exclusion Criteria:

          -  Previous vaccination with any Hep B vaccine (licensed or experimental).

          -  Treatment by immunosuppressant within 30 days of enrollment including but not limited
             to corticosteroids at a dose that is higher than an oral or injected physiological
             dose, or a prednisolone-equivalent dose &gt; 20 mg /day (Inhaled and topical steroids are
             allowed).

          -  Known history of immunological function impairment

          -  Pregnancy or breastfeeding

          -  Immunization with attenuated vaccines (e.g. MMR) within 4 weeks prior to enrollment

          -  Immunization with inactivated vaccines (e.g. influenza) within 2 weeks prior to
             enrolment

          -  Has received blood products or immunoglobulin within 90 days of enrollment or is
             likely to require blood products during the study period

          -  Subject in another clinical trial with an investigational drug or a biologic within 30
             days of enrollment

          -  Has received granulocyte-macrophage colony stimulating factor (G/GM-CSF) or
             erythropoietin (EPO) within 30 days of enrollment or likely to require GM-CSF or
             erythropoietin during the study period

          -  Any history of cancer requiring chemotherapy or radiation within 5 years of
             randomization or current disease.

          -  Any skin abnormality or tattoo that would limit post-vaccination injection site
             assessment

          -  History of allergic reactions or anaphylactic reaction to any vaccine component
             (Engerix-B® or Sci-B-Vac™)

          -  Unwilling, or unable in the opinion of the investigator, to comply with study
             requirements, including the use of an adequate birth control method

          -  Immediate family members of study center staff (parents, sibling, children)

          -  Current or past hepatitis B infection or prior vaccination as evidenced by HBV markers
             at screening

          -  Known hepatitis C infection or positive Hepatitis C serology at screening, unless
             treated and cured

          -  Known human immunodeficiency virus (HIV) infection or positive HIV serology at
             screening

          -  Renal impairment at screening

          -  Uncontrolled diabetes mellitus

          -  Uncontrolled hypertension

          -  Any laboratory test abnormality that would be considered of Grade 1 severity and is
             considered as clinically significant by the investigator. Grade 3 severity or above is
             exclusionary, regardless of clinical assessment.

          -  Diagnosis of advanced stage heart failure or Unstable Angina.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Diaz-Mitoma, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>VBI Vaccines</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bebi Yassin-Rajkumar, MS</last_name>
    <phone>1-866-574-7034</phone>
    <email>BYassin-Rajkumar@vbivaccines.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Accel Research Sites</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hayes Williams</last_name>
      <phone>205-757-8212</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amina Haggag</last_name>
      <phone>714-774-7777</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Rankin</last_name>
      <phone>386-740-0770</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Kutner</last_name>
      <phone>305-631-6704</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Segall</last_name>
      <phone>770-507-6867</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Turner</last_name>
      <phone>208-377-8653</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Levin</last_name>
      <phone>702-893-8968</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Beth Manning</last_name>
      <phone>216-682-0320</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl Griffin</last_name>
      <phone>405-602-3927</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Kirstein</last_name>
      <phone>801-542-8190</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Leroux-Roels</last_name>
      <phone>+329-332-3328</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Antwerp - Centre for the Evaluation of Vaccination</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Van Damme</last_name>
      <phone>+323-265-2538</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>BC Children's Hospital Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soren Gantt</last_name>
      <phone>604-875-2422</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Poliquin</last_name>
      <phone>204-474-8418</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canadian Center for Vaccinology</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Langley</last_name>
      <phone>902-470-8498</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curtis Cooper</last_name>
      <phone>613-737-8924</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Ward</last_name>
      <phone>514-624-7855</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Québec Université Laval</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Dionne</last_name>
      <phone>418-666-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Espoo Vaccine Research Clinic</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marita Paassilta</last_name>
      <phone>+358 9 420 8563</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki South Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiina Karppa</last_name>
      <phone>+358 9 6227 0363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Järvenpää Vaccine Research Clinic</name>
      <address>
        <city>Järvenpää</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anitta Ahonen</last_name>
      <phone>+358 9 2795 0100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kokkola Vaccine Research Clinic</name>
      <address>
        <city>Kokkola</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauliina Paavola</last_name>
      <phone>+358 40 190 4121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oulu Vaccine Research Clinic</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Satu Kokko</last_name>
      <phone>+358 50 531 0004</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pori Vaccine Research Clinic</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aino Forstén</last_name>
      <phone>+358 2 641 5200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seinäjoki Vaccine Research Clinic</name>
      <address>
        <city>Seinäjoki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miia Virta</last_name>
      <phone>+358 40 190 4119</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampere Vaccine Research Clinic</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miia Virta</last_name>
      <phone>+358 50 443 7254</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku Vaccine Research Clinic</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilkka Seppä</last_name>
      <phone>+358 2 236 1811</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2017</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

